Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

M. Lagarde; M. Hachem; N. Bernoud-Hubac; M. Picq; E. Véricel; M. Guichardant

doi:10.1016/j.plefa.2014.01.005

Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

M. Lagarde
, M. Hachem
, N. Bernoud-Hubac
, M. Picq
, E. Véricel
, M. Guichardant

Chemistry

INSA Lyon

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.

Original language	British English
Pages (from-to)	63-65
Number of pages	3
Journal	Prostaglandins Leukotrienes and Essential Fatty Acids
Volume	92
DOIs	https://doi.org/10.1016/j.plefa.2014.01.005
State	Published - 1 Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Blood-brain barrier
Metabolism
Stroke

Access to Document

10.1016/j.plefa.2014.01.005

OpenUrl availability

Full text

Cite this

@article{7e70329e8e724697a882f953b4cfaa4f,

title = "Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain",

abstract = "1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.",

keywords = "Blood-brain barrier, Metabolism, Stroke",

author = "M. Lagarde and M. Hachem and N. Bernoud-Hubac and M. Picq and E. V{\'e}ricel and M. Guichardant",

note = "Funding Information: The authors thank Inserm, INSA-Lyon, and ANR “Neuroprotect” 2008 , for their financial support, and Dr. Val{\'e}rie Pruneta-Deloche for human blood lipoprotein separation by FPLC. Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.plefa.2014.01.005",

language = "British English",

volume = "92",

pages = "63--65",

journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",

issn = "0952-3278",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

AU - Lagarde, M.

AU - Hachem, M.

AU - Bernoud-Hubac, N.

AU - Picq, M.

AU - Véricel, E.

AU - Guichardant, M.

N1 - Funding Information: The authors thank Inserm, INSA-Lyon, and ANR “Neuroprotect” 2008 , for their financial support, and Dr. Valérie Pruneta-Deloche for human blood lipoprotein separation by FPLC. Publisher Copyright: © 2014 Elsevier Ltd.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - 1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.

AB - 1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.

KW - Blood-brain barrier

KW - Metabolism

KW - Stroke

UR - https://www.scopus.com/pages/publications/84921439093

U2 - 10.1016/j.plefa.2014.01.005

DO - 10.1016/j.plefa.2014.01.005

M3 - Article

C2 - 24582148

AN - SCOPUS:84921439093

SN - 0952-3278

VL - 92

SP - 63

EP - 65

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

ER -

Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

Abstract

UN SDGs

Keywords

Access to Document

OpenUrl availability

Other files and links

Fingerprint

Cite this